menu
    • menu

    Company profile for Aviceda Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aviceda Therapeutics is an innovative biotech company focused on harnessing the promise of immune cells’ natural checkpoints, which modulate innate immune activity that is dysregulated in a diverse range of diseases characterized by chronic non-resolving inflammation. The strength of Aviceda’s therapeutic platform is its ability to stimulate a broad range of immune responses, including profound down regulation to address ...
    Aviceda Therapeutics is an innovative biotech company focused on harnessing the promise of immune cells’ natural checkpoints, which modulate innate immune activity that is dysregulated in a diverse range of diseases characterized by chronic non-resolving inflammation. The strength of Aviceda’s therapeutic platform is its ability to stimulate a broad range of immune responses, including profound down regulation to address inappropriate activity, and immune normalization to addresses diseases characterized by evasion of immune surveillance.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aviceda TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Broadway, 1 Broadway 14th Floor, Cambridge, MA 02142, USA
    Telephone
    Telephone
    +1 617.225.4343
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.avicedarx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aviceda Therapeutics Appoints Dr. Emmett, Jr. to Board
    Aviceda Therapeutics Appoints Dr. Emmett, Jr. to Board

    09 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250409496616/en/Aviceda-Therapeutics-Appoints-Ophthalmology-Innovator-and-Industry-Leader-Dr.-Emmett-T.-Cunningham-Jr.-to-Board-of-Directors

    BUSINESSWIRE
    09 Apr 2025
    Share Share
    Aviceda Therapeutics Appoints Dr. Jeffrey Nau as CEO for Growth
    Aviceda Therapeutics Appoints Dr. Jeffrey Nau as CEO for Growth

    01 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250401356648/en/Aviceda-Therapeutics-Appoints-Industry-Veteran-Dr.-Jeffrey-Nau-as-Chief-Executive-Officer-to-Lead-Next-Phase-of-Growth-and-Innovation

    BUSINESSWIRE
    01 Apr 2025
    Share Share
    Aviceda Raises $207.5M For AVD-104 Trials In Geographic Atrophy
    Aviceda Raises $207.5M For AVD-104 Trials In Geographic Atrophy

    07 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250107381552/en

    BUSINESSWIRE
    07 Jan 2025
    Share Share
    Aviceda raises $207M for geographic atrophy drug's ph. 3 journey
    Aviceda raises $207M for geographic atrophy drug's ph. 3 journey

    07 Jan 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/aviceda-raises-207m-series-c-take-geographic-atrophy-drug-through-phase-3

    FIERCE BIOTECH
    07 Jan 2025
    Share Share
    Aviceda Completes Phase 2b SIGLEC Study Enrollment for AVD-104
    Aviceda Completes Phase 2b SIGLEC Study Enrollment for AVD-104

    24 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240923774763/en

    BUSINESSWIRE
    24 Sep 2024
    Share Share
    Aviceda Therapeutics Adds Erin Lavelle To Board Of Directors
    Aviceda Therapeutics Adds Erin Lavelle To Board Of Directors

    10 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240910500769/en

    BUSINESSWIRE
    10 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search